Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

Drug Resistance Updates

Volumn 15, Issue 4, 2012, Pages 183-210

  Gonen, Nitzan ^a   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antifolates; Cancer; Chemotherapy; Drug resistance; Folate pools; Folate dependent enzymes; Folates; Influx and efflux transporters

Indexed keywords

CARBOPLATIN; FOLATE RECEPTOR; FOLATE TRANSPORTER; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; METHOTREXATE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PEMETREXED; PROTON COUPLED FOLATE TRANSPORTER; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG MECHANISM; DRUG STRUCTURE; FOLATE METABOLISM; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84865992002     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.07.002     Document Type: Article

References (417)

1. E.E. Abali Regulation of human dihydrofolate reductase activity and expression Vitamins & Hormones 79 2008 267 292
2. A.A. Adjei Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Journal of Clinical Oncology 28 2010 614 619
3. A.M. Albrecht, J.L. Biedler, and D.J. Hutchison Two different species of dihydrofolate reductase in mammalian cells differentially resistant to amethopterin and methasquin Cancer Research 32 1972 1539 1546
4. C.J. Allegra Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates Journal of Biological Chemistry 260 1985 9720 9726
5. C.J. Allegra Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate Journal of Biological Chemistry 262 1987 13520 13526
6. F.W. Alt Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells Journal of Biological Chemistry 253 1978 1357 1370
7. A. Antony Translational upregulation of folate receptors is mediated by homocysteine via RNA-heterogeneous nuclear ribonucleoprotein E1 interactions Journal of Clinical Investigation 113 2004 285 301
8. A.C. Antony Folate receptors: reflections on a personal odyssey and a perspective on unfolding truth Advance Drug Delivery Reviews 56 2004 1059 1066
9. J.R. Appleman Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase Journal of Biological Chemistry 263 1988 10304 10313
10. H. Arkin Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate Cancer Research 49 1989 6556 6561
11. Y.G. Assaraf Molecular basis of antifolate resistance Cancer and Metastasis Reviews 26 2007 153 181
12. Y.G. Assaraf The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 9 2006 227 246
13. Y.G. Assaraf Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts Journal of Biological Chemistry 267 1992 5776 5784
14. Y.G. Assaraf, and I.D. Goldman Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells Journal of Biological Chemistry 272 1997 17460 17466
15. Y.G. Assaraf Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets Journal of Theoretical Biology 240 2006 637 647
16. Y.G. Assaraf, A. Molina, and R.T. Schimke Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype Journal of the National Cancer Institute 81 1989 290 294
17. Y.G. Assaraf, A. Molina, and R.T. Schimke Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate Journal of Biological Chemistry 264 1989 18326 18334
18. Y.G. Assaraf Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells Journal of Biological Chemistry 278 2003 6680 6686
19. Y.G. Assaraf, and R.T. Schimke Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry Proceedings of the National Academy of Sciences United States of America 84 1987 7154 7158
20. Y.G. Assaraf, and J.I. Slotky Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine Journal of Biological Chemistry 268 1993 4556 4566
21. B. Atabay Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption Pediatric Hematology Oncology 27 2010 614 619
22. C.G. Azzoli Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial Journal of Thoracic Oncology 6 2011 1915 1922
23. J.E. Baggott, W.H. Vaughn, and B.B. Hudson Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide Biochemical Journal 236 1986 193 200
24. E. Bakos Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions Molecular Pharmacology 57 2000 760 768
25. D. Banerjee Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase Biochimica et Biophysica Acta 1587 2002 164 173
26. S.D. Banks Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations Cancer Chemotherapy and Pharmacology 33 1994 455 459
27. R.R. Barakat Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates Gynecologic Oncology 51 1993 54 60
28. K.W. Barbour, S.H. Berger, and F.G. Berger Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase Molecular Pharmacology 37 1990 515 518
29. M.J. Barnes Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines Clinical Cancer Research 5 1999 2548 2558
30. C.M. Baugh, C.L. Krumdieck, and M.G. Nair Polygammaglutamyl metabolites of methotrexate Biochemical and Biophysical Research Communications 52 1973 27 34
31. V. Bavetsias Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents Journal of Medicinal Chemistry 43 2000 1910 1926
32. G.P. Beardsley A new folate antimetabolite, 5,10-dideaza-5,6,7,8- tetrahydrofolate is a potent inhibitor of de novo purine synthesis Journal of Biological Chemistry 264 1989 328 333
33. V.M. Belkov Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation Blood 93 1999 1643 1650
34. T.S. Benepal, and I. Judson ZD9331: discovery to clinical development Anticancer Drugs 16 2005 1 9
35. J.R. Bertino The "induction" of leukocyte and erythrocyte dihydrofolate reductase by methotrexate. II. Clinical and pharmacologic studies Clinical Pharmacology & Therapeutics 6 1965 763 770
36. J.R. Bertino, A.R. Cashmore, and B.L. Hillcoat Induction" of dihydrofolate reductase: purification and properties of the "induced" human erythrocyte and leukocyte enzyme and normal bone marrow enzyme Cancer Research 30 1970 2372 2378
37. J.R. Bertino The "Induction" of dihydrofolic reductase activity in leukocytes and erythrocytes of patients treated with amethopterin Journal of Clinical Investigation 42 1963 466 475
38. J.R. Bertino Increased level of dihydrofolic reductase in leucocytes of patients treated with amethopterin Nature 193 1962 140 142
39. J.R. Bertino 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline (tmq), a potent non-classical folate antagonist inhibitor - I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo Biochemical Pharmacology 28 1979 1983 1987
40. G. Beutel Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors Clinical Cancer Research 11 2005 5487 5495
41. D. Bissett Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034 British Journal of Cancer 84 2001 308 312
42. C.D. Blanke S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach American Journal of Clinical Oncology 33 2010 117 120
43. N.M. Bleehen A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma British Journal of Cancer 72 1995 766 768
44. J.A. Bolton Retinoic acid-dependent upregulation of mouse folate receptor-alpha expression in embryonic stem cells, and conservation of alternative splicing patterns Gene 230 1999 215 224
45. T.J. Boritzki AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase Investigational New Drugs 14 1996 295 303
46. P. Borst, and R.O. Elferink Mammalian ABC transporters in health and disease Annual Review of Biochemistry 71 2002 537 592
47. E. Bram Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates Cancer Chemotherapy and Pharmacology 58 2006 826 834
48. K.E. Brigle Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line Journal of Biological Chemistry 270 1995 22974 22979
49. J.R. Brody Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy Cancer Research 66 2006 9369 9373
50. C. Bystroff, and J. Kraut Crystal structure of unliganded Escherichia coli dihydrofolate reductase. Ligand-induced conformational changes and cooperativity in binding Biochemistry 30 1991 2227 2239
51. W. Cao, and L.H. Matherly Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods Biochemical Journal 378 2004 201 206
52. S. Chattopadhyay, R.G. Moran, and I.D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Molecular Cancer Therapeutics 6 2007 404 417
53. S. Chattopadhyay Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability Oncologist 12 2007 808 815
54. S. Chattopadhyay The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line Molecular Cancer Therapeutics 5 2006 438 449
55. K.J. Chave Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms Gene 319 2003 167 175
56. Z.S. Chen Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system Cancer Research 62 2002 3144 3150
57. Q. Cheng Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells American Journal of Human Genetics 79 2006 264 274
58. Q. Cheng A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells Pharmacogenetics 14 2004 557 567
59. S. Cheradame Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activity Anticancer Drugs 10 1999 505 510
60. E. Chu, and C.J. Allegra The role of thymidylate synthase as an RNA binding protein BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 18 1996 191 198
61. E. Chu Thymidylate synthase inhibitors as anticancer agents: from bench to bedside Cancer Chemotherapy and Pharmacology Suppl. 1 52 2003 S80 S89
62. E. Chu Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase Proceedings of the National Academy of Sciences United States of America 88 1991 8977 8981
63. E. Chu Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro Biochemistry 32 1993 4756 4760
64. E. Chu Identification of an RNA binding site for human thymidylate synthase Proceedings of the National Academy of Sciences United States of America 90 1993 517 521
65. E. Chu Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells Molecular and Cellular Biology 14 1994 207 213
66. K.N. Chung Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates Journal of Clinical Investigation 91 1993 1289 1294
67. T. Ciuleanu A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers Investigational New Drugs 25 2007 385 390
68. A.R. Clamp A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer Cancer Chemotherapy and Pharmacology 61 2008 579 585
69. M.H. Cohen Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC) Oncologist 15 2010 1352 1358
70. M.H. Cohen, R. Justice, and R. Pazdur Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer Oncologist 14 2009 930 935
71. P.D. Cole Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance Cancer Research 61 2001 4599 4604
72. J.K. Coward, and J.J. McGuire Mechanism-based inhibitors of folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase: control of folylpoly-gamma-glutamate homeostasis as a drug target Vitamins & Hormones 79 2008 347 373
73. D. Cunningham Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials European Journal of Cancer 38 2002 478 486
74. E.G. de Vries A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer British Journal of Cancer 68 1993 641 644
75. R.G. Deeley, C. Westlake, and S.P. Cole Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiological Review 86 2006 849 899
76. M. Degardin A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck European Journal of Cancer 30A 1994 1044 1045
77. Y. Deng Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity Journal of Medicinal Chemistry 51 2008 5052 5063
78. I.K. Dev Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites Journal of Biological Chemistry 269 1994 1873 1882
79. L. DeVos Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations American Journal of Clinical Nutrition 88 2008 1149 1158
80. G.A. Diaz Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome Nature Genetics 22 1999 309 312
81. A.P. Dicker Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII Journal of Biological Chemistry 265 1990 8317 8321
82. B.C. Ding Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells Biochemical Pharmacology 61 2001 665 675
83. N.K. Diop-Bove Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line Molecular Cancer Therapeutics 8 2009 2424 2431
84. K.H. Dixon A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells Journal of Biological Chemistry 269 1994 17 20
85. B.J. Dolnick Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells Journal of Cell Biology 83 1979 394 402
86. B.A. Domin, Y.C. Cheng, and M.T. Hakala Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells Molecular Pharmacology 21 1982 231 238
87. J.C. Drake Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines Biochemical Pharmacology 51 1996 1349 1355
88. S. Drori Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake Journal of Biological Chemistry 275 2000 30855 30863
89. D.S. Duch Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase Cancer Research 53 1993 810 818
90. B. Dutta Cloning of the human thiamine transporter, a member of the folate transporter family Journal of Biological Chemistry 274 1999 31925 31929
91. H. Elnakat, and M. Ratnam Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy Advance Drug Delivery Reviews 56 2004 1067 1084
92. H. Elnakat, and M. Ratnam Role of folate receptor genes in reproduction and related cancers Frontiers in Bioscience 11 2006 506 519
93. J.J. Eloranta Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter Molecular Pharmacology 76 2009 1062 1071
94. P.C. Elwood The divergent 5' termini of the alpha human folate receptor (hFR) mRNAs originate from two tissue-specific promoters and alternative splicing: characterization of the alpha hFR gene structure Biochemistry 36 1997 1467 1478
95. E.A. Ercikan-Abali Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region Biochemistry 36 1997 12317 12322
96. E. Ercikan Translational regulation of the synthesis of dihydrofolate reductase Advances in Experimental Medicine and Biology 338 1993 537 540
97. S. Falk Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma British Journal of Cancer 95 2006 450 456
98. S. Farber Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin) New England Journal of Medicine 238 1948 787 793
99. P.L. Ferguson, and W.F. Flintoff Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion Journal of Biological Chemistry 274 1999 16269 16278
100. A.J. Ferreri Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas British Journal of Haematology 126 2004 657 664
101. L.G. Feun Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration Journal of Clinical Oncology 9 1991 464 467
102. L.G. Feun Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma American Journal of Clinical Oncology 18 1995 488 490
103. G.F. Fleming, and R.L. Schilsky Antifolates: the next generation Seminars in Oncology 19 1992 707 719
104. J.C. Fleming The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter Nature Genetics 22 1999 305 308
105. W.F. Flintoff, and K. Essani Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate Biochemistry 19 1980 4321 4327
106. W.F. Flintoff Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas Biochimica et Biophysica Acta 1690 2004 110 117
107. F.M. Foss Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma Expert Opinion on Drug Metabolism & Toxicology 7 2011 1141 1152
108. J.T. Fox, and P.J. Stover Folate-mediated one-carbon metabolism Vitamins & Hormones 79 2008 1 44
109. S.J. Freemantle Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694 British Journal of Cancer 71 1995 925 930
110. D.W. Fry, and J.A. Besserer Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates Cancer Research 48 1988 6986 6991
111. J. Galivan Glutamyl hydrolase. pharmacological role and enzymatic characterization Pharmacology & Therapeutics 85 2000 207 215
112. E. Galvani, G.J. Peters, and E. Giovannetti Thymidylate synthase inhibitors for non-small cell lung cancer Expert Opinion on Investigational Drugs 20 2011 1343 1356
113. D.D. Gibbs BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors Cancer Research 65 2005 11721 11728
114. R.G. Gish Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin Journal of Clinical Oncology 25 2007 3069 3075
115. J.H. Goldie A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells European Journal of Cancer 16 1980 1539 1546
116. I.D. Goldman The characteristics of the membrane transport of amethopterin and the naturally occurring folates Annals of the New York Academy of Sciences 186 1971 400 422
117. I.D. Goldman The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts Molecular Pharmacology 10 1974 257 274
118. I.D. Goldman, N.S. Lichtenstein, and V.T. Oliverio Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell Journal of Biological Chemistry 243 1968 5007 5017
119. N. Gonen, and Y.G. Assaraf The obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1 Journal of Biological Chemistry 285 2010 33602 33613
120. N. Gonen, E.E. Bram, and Y.G. Assaraf PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells Biochemical and Biophysical Research Communications 376 2008 787 792
121. M. Gong Isolation and characterization of genomic sequences involved in the regulation of the human reduced folate carrier gene (RFC1) Gene 233 1999 21 31
122. R. Gorlick Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression Blood 89 1997 1013 1018
123. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nature Reviews Cancer 2 2002 48 58
124. W. Guo Mechanisms of methotrexate resistance in osteosarcoma Clinical Cancer Research 5 1999 621 627
125. L.L. Habeck Substrate specificity of mammalian folylpolyglutamate synthetase for 5, 10-dideazatetrahydrofolate analogs Molecular Pharmacology 48 1995 326 333
126. D.A. Haber, and R.T. Schimke Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes Cell 26 1981 355 362
127. J. Hainsworth, I. Vergote, and J. Janssens A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours Anticancer Drugs 1 14 Suppl 2003 S13 S19
128. M.T. Hakala On the role of drug penetration in amethopterin resistance of Sarcoma-180 cells in vitro Biochimica et Biophysica Acta 102 1965 198 209
129. B.A. Hamkalo Ultrastructural features of minute chromosomes in a methotrexate-resistant mouse 3T3 cell line Proceedings of the National Academy of Sciences United States of America 82 1985 1126 1130
130. M.H. Hanlon, and R. Ferone In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase Cancer Research 56 1996 3301 3306
131. H. Hao, H. Qi, and M. Ratnam Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites Blood 101 2003 4551 4560
132. H. Hayashi Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population Biological and Pharmaceutical Bulletin 30 2007 839 841
133. M. Hazarika FDA drug approval summaries: pemetrexed (Alimta) Oncologist 9 2004 482 488
134. C. Heidelberger Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
135. G.B. Henderson, and E.M. Zevely Structural requirements for anion substrates of the methotrexate transport system in L1210 cells Archives of Biochemistry and Biophysics 221 1983 438 446
136. A.R. Hilgenbrink, and P.S. Low Folate receptor-mediated drug targeting: from therapeutics to diagnostics Journal of Pharmaceutical Sciences 94 2005 2135 2146
137. B.T. Hill Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate Cancer Research 39 1979 2440 2446
138. B.L. Hillcoat, V. Swett, and J.R. Bertino Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate Proceedings of the National Academy of Sciences United States of America 58 1967 1632 1637
139. J.H. Hooijberg Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer Research 59 1999 2532 2535
140. J.H. Hooijberg The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis Biochemical Pharmacology 65 2003 765 771
141. N. Horie Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase Cell Structure and Function 20 1995 191 197
142. R.C. Horns Jr., W.J. Dower, and R.T. Schimke Gene amplification in a leukemic patient treated with methotrexate Journal of Clinical Oncology 2 1984 2 7
143. Z. Hou Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter Journal of Biological Chemistry 287 2011 4982 4995
144. B. Hough A phase II study of single agent OSI-7904L in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) Journal of Clinical Oncology 27 2009 (suppl; abstr e17005)
145. C.T. Hsueh, and B.J. Dolnick Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells Biochemical Pharmacology 47 1994 1019 1027
146. M. Hu, and J. Chen Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model Molecular Pharmacology 1 2004 194 200
147. C.T. Hughey Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine Advances in Experimental Medicine and Biology 339 1993 67 76
148. I. Ifergan, and Y.G. Assaraf Molecular mechanisms of adaptation to folate deficiency Vitamins & Hormones 79 2008 99 143
149. I. Ifergan, G. Jansen, and Y.G. Assaraf The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation RFC as a double edged sword in folate homeostasis, Journal of Biological Chemistry 283 2008 20687 20695
150. I. Ifergan Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity Cancer 98 2003 1958 1966
151. A.L. Jackman, and A.H. Calvert Folate-based thymidylate synthase inhibitors as anticancer drugs Annals of Oncology 6 1995 871 881
152. A.L. Jackman Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines British Journal of Cancer 71 1995 914 924
153. A.L. Jackman Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase Clinical Cancer Research 3 1997 911 921
154. A.L. Jackman ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study Cancer Research 51 1991 5579 5586
155. A.L. Jackman, D.S. Theti, and D.D. Gibbs Antifolates targeted specifically to the folate receptor Advance Drug Delivery Reviews 56 2004 1111 1125
156. R.C. Jackson Biochemical pharmacology of the lipophilic antifolate, trimetrexate Advances in Enzyme Regulation 22 1984 187 206
157. R.C. Jackson, and K.R. Harrap Studies with a mathematical model of folate metabolism Archives of Biochemistry and Biophysics 158 1973 827 841
158. R.C. Jackson, L.I. Hart, and K.R. Harrap Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases Cancer Research 36 1976 1991 1997
159. R.C. Jackson, D. Niethammer, and L.I. Hart Reactivation of dihydrofolate reductase inhibted by methotrexate or aminopterin Archives of Biochemistry and Biophysics 182 1977 646 656
160. G. Jansen Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates. Exploitation for Folate Chemotherapy and Immunotherapy 1999 Humana Press Inc. Totowa, NJ
161. G. Jansen Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration Molecular Pharmacology 55 1999 761 769
162. G. Jansen A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance Journal of Biological Chemistry 273 1998 30189 30198
163. G. Jansen Membrane transport properties and biological activity of stereo-isomers of glycinamide ribonucleotide formyltransferase (GARFT) inhibitors AG2032 and AG2034 Pteridines 20 2010 109 114
164. G. Jansen Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates Journal of Biological Chemistry 265 1990 18272 18277
165. A. Jarmula Antifolate inhibitors of thymidylate synthase as anticancer drugs Mini-Reviews in Medicinal Chemistry 10 2010 1211 1222
166. M. Jhawer Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma Investigational New Drugs 25 2007 85 94
167. T.B. Johnson, M.G. Nair, and J. Galivan Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells Cancer Research 48 1988 2426 2431
168. B.A. Kamen Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles Journal of Biological Chemistry 263 1988 13602 13609
169. M.A. Kane Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells Journal of Clinical Investigation 81 1988 1398 1406
170. I.B. Kastrup Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma European Journal of Haematology 80 2008 61 66
171. R.J. Kaufman, P.C. Brown, and R.T. Schimke Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes Proceedings of the National Academy of Sciences United States of America 76 1979 5669 5673
172. Y. Kaufman Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia
173. Y. Kaufman Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss Blood 107 2006 3288 3294
174. L.E. Kelemen The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? International Journal of Cancer 119 2006 243 250
175. K.M. Kelley, B.G. Rowan, and M. Ratnam Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting Cancer Research 63 2003 2820 2828
176. M. Khorsand Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder Investigational New Drugs 15 1997 157 163
177. W.D. Klohs Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U Cancer Letters 31 1986 253 260
178. H. Kobayashi, Y. Takemura, and H. Miyachi Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor Cancer Chemotherapy and Pharmacology 42 1998 105 110
179. L.M. Krug 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer Clinical Cancer Research 9 2003 2072 2078
180. L.M. Krug Phase I and pharmacokinetic study of 10-propargyl-10- deazaaminopterin, a new antifolate Clinical Cancer Research 6 2000 3493 3498
181. S. Kugel Desmoulin Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter Molecular Pharmacology 80 2011 1096 1107
182. H. Kusuhara Reduced folate derivatives are endogenous substrates for cMOAT in rats American Journal of Physiology 275 1998 G789 G796
183. V. Labay Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness Nature Genetics 22 1999 300 304
184. J.F. Lacerda Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection Blood 85 1995 2675 2679
185. A.H. Laftah Haem and folate transport by proton-coupled folate transporter/haem carrier protein 1 (SLC46A1) British Journal of Nutrition 101 2009 1150 1156
186. I. Lasry A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function Blood 112 2008 2055 2061
187. L.K. Lassiter Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy Clinical Genitourinary Cancer 6 2008 31 35
188. S.A. Lawrence, J.C. Hackett, and R.G. Moran Tetrahydrofolate recognition by the mitochondrial folate transporter Journal of Biological Chemistry 286 2011 31480 31489
189. C.P. Leamon Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue Cancer Research 68 2008 9839 9844
190. G.J. Leclerc Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy Leukemia 24 2010 552 562
191. K. Lee, A.J. Klein-Szanto, and G.D. Kruh Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells Journal of the National Cancer Institute 92 2000 1934 1940
192. A.S. Levy Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study Journal of Pediatric Hematology Oncology 25 2003 688 695
193. W.S. Lewis Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers Journal of Biological Chemistry 270 1995 5057 5064
194. J. Li Xenopus reduced folate carrier regulates neural crest development epigenetically PLoS One 6 2011 pe27198
195. W.W. Li Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines Cancer Research 52 1992 3908 3913
196. W.W. Li, W.P. Tong, and J.R. Bertino Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate Clinical Cancer Research 1 1995 631 636
197. W.W. Li Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX) Advances in Experimental Medicine and Biology 338 1993 635 638
198. E. Liani Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines International Journal of Cancer 103 2003 587 599
199. B.F. Lin, R.F. Huang, and B. Shane Regulation of folate and one-carbon metabolism in mammalian cells. III. Role of mitochondrial folylpoly-gamma- glutamate synthetase Journal of Biological Chemistry 268 1993 21674 21679
200. X. Lin Role of cysteine amino acid residues on the RNA binding activity of human thymidylate synthase Nucleic Acids Research 31 2003 4882 4887
201. X. Lin Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA Nucleic Acids Research 28 2000 1381 1389
202. M. Liu Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates Journal of Biological Chemistry 280 2005 5588 5597
203. X.Y. Liu, and L.H. Matherly Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis Biochimica et Biophysica Acta 1564 2002 333 342
204. C. Louvet A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients Bull Cancer 91 2004 279 284
205. P.S. Low, and S.A. Kularatne Folate-targeted therapeutic and imaging agents for cancer Current Opinion in Chemical Biology 13 2009 256 262
206. K. Lu Mechanisms of resistance to N-[5-[N-(3, 4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line Biochemical Pharmacology 50 1995 391 398
207. Y. Lu, and P.S. Low Folate-mediated delivery of macromolecular anticancer therapeutic agents Advance Drug Delivery Reviews 54 2002 675 693
208. G. Lurje Thymidylate synthase gene variations: predictive and prognostic markers Molecular Cancer Therapeutics 8 2009 1000 1007
209. C. Manegold Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma Seminars in Oncology 30 2003 32 36
210. J.L. Marshall, and R.J. DeLap Clinical pharmacokinetics and pharmacology of trimetrexate Clinical Pharmacokinetics 26 1994 190 200
211. M. Martin Clinical experience with pemetrexed in breast cancer Seminars in Oncology 33 2006 S15 S18
212. M. Masuda Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats Cancer Research 57 1997 3506 3510
213. L.H. Matherly, and S.M. Angeles Role of N-glycosylation in the structure and function of the methotrexate membrane transporter from CCRF-CEM human lymphoblastic leukemia cells Biochemical Pharmacology 47 1994 1094 1098
214. L.H. Matherly, S.M. Angeles, and C.A. Czajkowski Characterization of transport-mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors Journal of Biological Chemistry 267 1992 23253 23260
215. L.H. Matherly, and D.I. Goldman Membrane transport of folates Vitamins & Hormones 66 2003 403 456
216. L.H. Matherly Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children Blood 90 1997 578 589
217. R. Mauritz Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer Clinical Colorectal Cancer 8 2009 146 154
218. R. Mauritz Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis Biochemical Pharmacology 63 2002 105 115
219. M.W. McBurney, and G.F. Whitmore Characterization of a Chinese hamster cell with a temperature-sensitive mutation in folate metabolism Cell 2 1974 183 188
220. D.E. McCloskey Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines Journal of Biological Chemistry 266 1991 6181 6187
221. J. McGuire Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure Oncology Research 7 1995 535 543
222. J.J. McGuire Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines Leukemia 7 1993 1996 2003
223. J.J. McGuire Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products Journal of Biological Chemistry 255 1980 5776 5788
224. J.J. McGuire, and C.A. Russell Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines Oncology Research 10 1998 193 200
225. R.S. McIvor, and C.C. Simonsen Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells Nucleic Acids Research 18 1990 7025 7032
226. P.W. Melera Phenotypic expression in Escherichia coli and nucleotide sequence of two Chinese hamster lung cell cDNAs encoding different dihydrofolate reductases Molecular and Cellular Biology 4 1984 38 48
227. P.W. Melera, J.P. Davide, and H. Oen Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines Journal of Biological Chemistry 263 1988 1978 1990
228. E. Meyer A novel PCFT gene mutation (p.Cys66LeufsX99) causing hereditary folate malabsorption Molecular Genetics and Metabolism 99 2010 325 328
229. E. Mini Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells Cancer Research 45 1985 317 324
230. H. Miyachi Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate Cancer Letters 88 1995 93 99
231. T.S. Mok A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma Cancer Chemotherapy and Pharmacology 44 1999 307 311
232. C. Morales Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells Molecular Cancer Therapeutics 8 2009 424 432
233. R.G. Moran Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview Seminars in Oncology 26 1999 24 32
234. R.G. Moran, W.C. Werkheiser, and S.F. Zakrzewski Folate metabolism in mammalian cells in culture. I Partial characterization of the folate derivatives present in L1210 mouse leukemia cells Journal of Biological Chemistry 251 1976 3569 3575
235. J.A. Moscow Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells Cancer Research 55 1995 3790 3794
236. C. Muller Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation Current Pharmaceutical Design 18 2012 1058 1083
237. R.W. Naumann, and R.L. Coleman Management strategies for recurrent platinum-resistant ovarian cancer Drugs 71 2011 1397 1412
238. R.W. Naumann PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer Journal of Clinical Oncology 2011 29 (suppl; abstr 5045)
239. I. Niculescu-Duvaz Thymitaq (Zarix) Current Opinion in Investigational Drugs 2 2001 693 705
240. D. Niethammer, and R.C. Jackson Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells European Journal of Cancer 11 1975 845 854
241. Z. Nimec, and J. Galivan Regulatory aspects of the glutamylation of methotrexate in cultured hepatoma cells Archives of Biochemistry and Biophysics 226 1983 671 680
242. J.H. Nunberg Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexate-resistant Chinese hamster ovary cell line Proceedings of the National Academy of Sciences United States of America 75 1978 5553 5556
243. B.M. O'Connor Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5, 8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor Cancer Research 52 1992 1137 1143
244. O.A. O'Connor Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies Journal of Clinical Oncology 27 2009 4357 4364
245. O.A. O'Connor Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study Journal of Clinical Oncology 29 2011 1182 1189
246. O. Obajimi, J.C. Keen, and P.W. Melera Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence The Prostate 69 2009 1206 1221
247. J. Organista-Nava Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico Leukemia Research 34 2010 728 732
248. S.S. Pao, I.T. Paulsen, and M.H. Saier Jr. Major facilitator superfamily Microbiology and Molecular Biology Reviews 62 1998 1 34
249. N. Parker Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay Analytical Biochemistry 338 2005 284 293
250. C.M. Paulos Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis Advance Drug Delivery Reviews 56 2004 1205 1217
251. G. Pizzorno 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines Journal of Biological Chemistry 268 1993 1017 1023
252. G. Pizzorno Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug Cancer Research 49 1989 5275 5280
253. G. Pizzorno Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug Cancer Research 48 1988 2149 2155
254. G. Pizzorno (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells Cancer Research 51 1991 2291 2295
255. G. Pizzorno Multifactorial resistance to 5, 10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM Cancer Research 55 1995 566 573
256. G. Pizzorno Intracellular metabolism of 5, 10-dideazatetrahydrofolic acid in human leukemia cell lines Molecular Pharmacology 39 1991 85 89
257. O. Polgar, R.W. Robey, and S.E. Bates ABCG2: structure, function and role in drug response Expert Opinion on Drug Metabolism & Toxicology 4 2008 1 15
258. P.D. Prasad Molecular cloning of the human placental folate transporter Biochemical and Biophysical Research Communications 206 1995 681 687
259. A. Qiu Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption Cell 127 2006 917 928
260. A. Qiu Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction American Journal of Physiology Cell Physiology 293 2007 C1669 C1678
261. A.C. Racanelli Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition Cancer Research 69 2009 5467 5474
262. J.S. Rader A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer Gynecologic Oncology 91 2003 318 325
263. A. Rajgopal SLC19A3 encodes a second thiamine transporter ThTr2 Biochimica et Biophysica Acta 1537 2001 175 178
264. M. Ratnam Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA Biochemistry 28 1989 8249 8254
265. M.S. Ray Phase I study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis Journal of the National Cancer Institute 85 1993 1154 1159
266. R.T. Reilly, A.M. Forsthoefel, and F.G. Berger Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase Archives of Biochemistry and Biophysics 342 1997 338 343
267. M.S. Rhee Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity Cancer Research 53 1993 2227 2230
268. A.D. Ricart Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors Clinical Cancer Research 14 2008 7947 7955
269. L. Righi Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy Journal of Clinical Oncology 28 2010 1534 1539
270. J.D. Roberts Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation Cancer Chemotherapy and Pharmacology 45 2000 103 110
271. C. Rocha Lima A phase I study of talotrexin (PT-523) in patients with relapsed or refractory non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 24 2006 7142 No. 18S (June 20 Supplement)
272. H. Rochman, J. Selhub, and T. Karrison Folate binding protein and the estrogen receptor in breast cancer Cancer Detection and Prevention 8 1985 71 75
273. A. Rosowsky, H. Bader, and J.H. Freisheim Synthesis and biological activity of methotrexate analogues with two acid groups and a hydrophobic aromatic ring in the side chain Journal of Medicinal Chemistry 34 1991 574 579
274. A. Rosowsky Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523) Journal of Medicinal Chemistry 41 1998 5310 5319
275. J.F. Ross, P.K. Chaudhuri, and M. Ratnam Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications Cancer 73 1994 2432 2443
276. J.F. Ross Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia Cancer 85 1999 348 357
277. B.J. Roth Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group Investigational New Drugs 20 2002 425 429
278. K.G. Rothberg The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway Journal of Cell Biology 110 1990 637 649
279. L. Rothem, A. Aronheim, and Y.G. Assaraf Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells Journal of Biological Chemistry 278 2003 8935 8941
280. L. Rothem Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines Biochemical Journal 367 2002 741 750
281. L. Rothem, M. Stark, and Y.G. Assaraf Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene Molecular Pharmacology 66 2004 1536 1543
282. L. Rothem Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation Journal of Biological Chemistry 279 2004 374 384
283. M.G. Rots mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method Leukemia 14 2000 2166 2175
284. K. Roy Chromosomal localization of the murine RFC-1 gene encoding a folate transporter and its amplification in an antifolate resistant variant overproducing the transporter Cancer Genetics and Cytogenetics 105 1998 29 38
285. K. Roy Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme Journal of Biological Chemistry 272 1997 6903 6908
286. B.G. Rumberger Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity Cancer Communication 2 1990 305 310
287. E. Sadasivan, M.M. Cedeno, and S.P. Rothenberg Characterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein Journal of Biological Chemistry 269 1994 4725 4735
288. M.H. Saier Jr. A functional-phylogenetic system for the classification of transport proteins Journal of Cellular Biochemistry Supplement 32-33 1999 84 94
289. Y. Saikawa Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells Journal of Biological Chemistry 268 1993 5293 5301
290. Y. Saikawa Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity Biochemistry 34 1995 9951 9961
291. M.D. Salazar, and M. Ratnam The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer and Metastasis Reviews 26 2007 141 152
292. J.D. Schiesel Oral piritrexim - a phase II study in patients with advanced soft tissue sarcoma Investigational New Drugs 10 1992 97 98
293. V. Schirch, and W.B. Strong Interaction of folylpolyglutamates with enzymes in one-carbon metabolism Archives of Biochemistry and Biophysics 269 1989 371 380
294. S.R. Schlemmer, and F.M. Sirotnak Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells Biochemical Pharmacology 49 1995 1427 1433
295. F.A. Schmid New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice Cancer Treatment Reports 69 1985 551 553
296. E. Schneider, and T.J. Ryan Gamma-glutamyl hydrolase and drug resistance Clinica Chimica Acta 374 2006 25 32
297. R.M. Schultz Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs Seminars in Oncology 26 1999 68 73
298. J. Schulz ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial American Journal of Clinical Oncology 27 2004 337 342
299. G. Schwartz A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies Clinical Cancer Research 7 2001 1901 1911
300. A. Shafran ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates Cancer Research 65 2005 8414 8422
301. M. Shayeghi Identification of an intestinal heme transporter Cell 122 2005 789 801
302. F. Shen Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity Biochemistry 33 1994 1209 1215
303. F. Shen Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity Biochemistry 34 1995 5660 5665
304. C. Shih LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Research 57 1997 1116 1123
305. D.S. Shin Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption Molecular Genetics and Metabolism 103 2011 33 37
306. D.S. Shin A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding American Journal of Physiology Cell Physiology 2012
307. E.E. Sierra pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH Biochemical Pharmacology 53 1997 223 231
308. E.E. Sierra, and I.D. Goldman Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function Biochemical Pharmacology 55 1998 1505 1512
309. J. Sigmond Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression Biochemical Pharmacology 66 2003 431 438
310. C.C. Simonsen, and A.D. Levinson Isolation and expression of an altered mouse dihydrofolate reductase cDNA Proceedings of the National Academy of Sciences United States of America 80 1983 2495 2499
311. M.J. Singer Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks Proceedings of the National Academy of Sciences United States of America 97 2000 7921 7926
312. F.M. Sirotnak Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer Cancer Research 45 1985 3992 4000
313. F.M. Sirotnak A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice Cancer Chemotherapy and Pharmacology 42 1998 313 318
314. F.M. Sirotnak New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties Cancer Chemotherapy and Pharmacology 12 1984 18 25
315. F.M. Sirotnak New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models Cancer Chemotherapy and Pharmacology 12 1984 26 30
316. F.M. Sirotnak, and R.C. Donsbach The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells Cancer Research 34 1974 332 340
317. F.M. Sirotnak, S. Kurita, and D.J. Hutchison On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia Cancer Research 28 1968 75 80
318. F.M. Sirotnak Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo Cancer Research 41 1981 4447 4452
319. F.M. Sirotnak 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties NCI Monographs 1987 127 131
320. N. Skacel Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment Journal of Biological Chemistry 280 2005 22721 22731
321. D. Smith, and N. Gallagher A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer European Journal of Cancer 39 2003 1377 1383
322. G. Smith GW1843, a Potent, Noncompetitive Thymidylate Synthase Inhibitor - Preclinical and Preliminary Clinical Studies 1999 Humana Press, Inc.
323. G.K. Smith Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid Cancer Research 55 1995 6117 6125
324. H.T. Spencer Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate Leukemia 10 1996 439 446
325. S. Srimatkandada Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug Journal of Biological Chemistry 264 1989 3524 3528
326. M. Stark, and Y.G. Assaraf Loss of Sp1 function via inhibitory phosphorylation in antifolate-resistant human leukemia cells with down-regulation of the reduced folate carrier Blood 107 2006 708 715
327. M. Stark, N. Gonen, and Y.G. Assaraf Functional elements in the minimal promoter of the human proton-coupled folate transporter Biochemical and Biophysical Research Communications 388 2009 79 85
328. M. Stark Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate Molecular Pharmacology 64 2003 220 227
329. M. Stark Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia Blood 113 2009 4362 4369
330. E.L.R. Stockstad Historical perspective on key advances in the biochemistry and physiology of folates Folic Acid Metabolism in Health and Disease 1990 Wiley-Liss New York pp. 1-21
331. K. Stuart A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma Cancer 86 1999 410 414
332. V.F. Surmont, and J.P. van Meerbeeck Raltitrexed in mesothelioma Expert Review of Anticancer Therapy 11 2011 1481 1490
333. G. Szakacs Targeting multidrug resistance in cancer Nature Reviews Drug Discovery 5 2006 219 234
334. N. Tai Identification of critical amino acid residues on human dihydrofolate reductase protein that mediate RNA recognition Nucleic Acids Research 30 2002 4481 4488
335. N. Tai Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA Biochemical Journal 378 2004 999 1006
336. N. Tai Identification of a cis-acting element of human dihydrofolate reductase mRNA Biochemical and Biophysical Research Communications 369 2008 795 800
337. N. Tai Translational autoregulation of thymidylate synthase and dihydrofolate reductase Frontiers in Bioscience 9 2004 2521 2526
338. Y. Takemura, H. Kobayashi, and H. Miyachi Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs Anticancer Drugs 10 1999 677 683
339. K. Takezawa Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer British Journal of Cancer 104 2011 1594 1601
340. C.H. Takimoto New antifolates: pharmacology and clinical applications Oncologist 1 1996 68 81
341. E.C. Taylor A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3, 4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase, Journal of Medicinal Chemistry 35 1992 4450 4454
342. I.W. Taylor Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake Cancer Research 45 1985 978 982
343. D.S. Theti Selective delivery of CB300638, a cyclopenta[g]quinazoline- based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor Cancer Research 63 2003 3612 3618
344. R.J. Thomas, M. Williams, and J. Garcia-Vargas Lessons learned from raltitrexed - quality assurance, patient education and intensive supportive drugs to optimise tolerability Clinical Oncology (R Coll Radiol) 15 2003 227 232
345. C.A. Thompson FDA approves pralatrexate for treatment of rare lymphoma American Journal of Health-System Pharmacy 66 2009 p1890
346. A.S. Tibbetts, and D.R. Appling Compartmentalization of Mammalian folate-mediated one-carbon metabolism Annual Review of Nutrition 30 2010 57 81
347. S.A. Titus, and R.G. Moran Retrovirally mediated complementation of the glyB phenotype, Cloning of a human gene encoding the carrier for entry of folates into mitochondria Journal of Biological Chemistry 275 2000 36811 36817
348. B. Tolner, K. Roy, and F.M. Sirotnak Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5' end heterogeneity Gene 211 1998 331 341
349. Y. Tong Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells Journal of Biological Chemistry 273 1998 11611 11618
350. T. Tran Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting Cancer Research 65 2005 4431 4441
351. J.M. Trent Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma Journal of Clinical Oncology 2 1984 8 15
352. A. Tse, and R.G. Moran Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites Journal of Biological Chemistry 273 1998 25944 25952
353. W.C. Uen A phase II study of piritrexim in patients with advanced squamous head and neck cancer Cancer 69 1992 1008 1011
354. C.M. Ulrich Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene Cancer Epidemiology, Biomarkers & Prevention 9 2000 1381 1385
355. E.S. Unal N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT) Biochimica et Biophysica Acta 1778 2008 1407 1414
356. R.A. van Aubel The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP Journal of the American Society of Nephrology 13 2002 595 603
357. G.M. van Dam Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results Nature Medicine 17 2011 1315 1319
358. C.L. van der Wilt Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors Cancer Research 61 2001 3675 3681
359. B. van Triest Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression Biochemical Pharmacology 53 1997 1855 1866
360. N.J. Vogelzang Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma Journal of Clinical Oncology 21 2003 2636 2644
361. E.E. Vokes A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer Cancer 67 1991 2253 2257
362. E.L. Volk Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux Cancer Research 60 2000 3514 3521
363. E.L. Volk, and E. Schneider Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter Cancer Research 63 2003 5538 5543
364. J. Walling From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates Investigational New Drugs 24 2006 37 77
365. H. Wang Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia Blood 96 2000 3529 3536
366. L. Wang Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry Journal of Medicinal Chemistry 53 2010 1306 1318
367. L. Wang Synthesis and Biological Activity of 6-Substituted Pyrrolo[2, 3-d]pyrimidine Thienoyl Regioisomers as Inhibitors of de Novo Purine Biosynthesis with Selectivity for Cellular Uptake by High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier Journal of Medicinal Chemistry 55 2012 1758 1770
368. W. Wang Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors Cancer Research 61 2001 5505 5510
369. X. Wang Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates Biochemical Pharmacology 44 1992 1898 1901
370. Y. Wang, R. Zhao, and I.D. Goldman Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier Clinical Cancer Research 10 2004 6256 6264
371. S. Webber AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies Cancer Chemotherapy and Pharmacology 37 1996 509 517
372. G.R. Westerhof Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein Cancer Research 55 1995 3795 3802
373. G.R. Westerhof Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity Molecular Pharmacology 48 1995 459 471
374. Y. Wettergren Low expression of reduced folate carrier-1 and folylpolyglutamate synthase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients Cancer Detection and Prevention 29 2005 348 355
375. J.R. Whetstine, R.M. Flatley, and L.H. Matherly The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter Biochemical Journal 367 2002 629 640
376. J.R. Whetstine Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers Clinical Cancer Research 7 2001 3416 3422
377. J.R. Whetstine, and L.H. Matherly The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element. Basis for tissue-specific gene expression Journal of Biological Chemistry 276 2001 6350 6358
378. J.R. Whetstine, T.L. Witt, and L.H. Matherly The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism Journal of Biological Chemistry 277 2002 43873 43880
379. J.C. White Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. Studies with pure enzyme and computer modeling using network thermodynamics Journal of Biological Chemistry 254 1979 10889 10895
380. J.C. White, and I.D. Goldman Methotrexate resistance in al L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport, Computer simulations based on network thermodynamics Journal of Biological Chemistry 256 1981 5722 5727
381. J.C. White, S. Loftfield, and I.D. Goldman The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of (14C)formate incorporation into nucleic acids and protein Molecular Pharmacology 11 1975 287 297
382. P. Wielinga The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates Cancer Research 65 2005 4425 4430
383. F.M. Williams Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake Journal of Biological Chemistry 269 1994 5810 5816
384. S.C. Wong Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells Journal of Biological Chemistry 270 1995 17468 17475
385. S.C. Wong Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier Biochimica et Biophysica Acta 1375 1998 6 12
386. J. Worm Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells Journal of Biological Chemistry 276 2001 39990 40000
387. J.E. Wright Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues Biochemical Pharmacology 60 2000 41 46
388. J.E. Wright Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity Biochemical Pharmacology 65 2003 1427 1433
389. W. Xia, and P.S. Low Folate-targeted therapies for cancer Journal of Medicinal Chemistry 53 2010 6811 6824
390. T.L. Yang-Feng Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization Biochemical and Biophysical Research Communications 210 1995 874 879
391. R. Yang Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier BMC Cancer 8 2008 p124
392. R. Yang Polymorphisms and methylation of the reduced folate carrier in osteosarcoma Clinical Orthopaedics and Related Research 466 2008 2046 2051
393. R. Yang Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples Clinical Cancer Research 9 2003 837 844
394. H. Zeng Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport Cancer Research 61 2001 7225 7232
395. H. Zeng Transport of amphipathic anions by human multidrug resistance protein 3 Cancer Research 60 2000 4779 4784
396. C.C. Zhang, T.J. Boritzki, and R.C. Jackson An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint Cancer Chemotherapy and Pharmacology 41 1998 223 228
397. L. Zhang Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy Clinical Cancer Research 4 1998 2169 2177
398. R. Zhao, Y.G. Assaraf, and I.D. Goldman A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function Journal of Biological Chemistry 273 1998 19065 19071
399. R. Zhao, Y.G. Assaraf, and I.D. Goldman A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate Journal of Biological Chemistry 273 1998 7873 7879
400. R. Zhao The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate Clin Cancer Research 6 2000 3687 3695
401. R. Zhao Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier Clinical Cancer Research 10 2004 8735 8742
402. R. Zhao, F. Gao, and I.D. Goldman Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells Biochemical Pharmacology 61 2001 857 865
403. R. Zhao, F. Gao, and I.D. Goldman Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells American Journal of Physiology Cell Physiology 282 2002 C1512 C1517
404. R. Zhao A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier Clin Cancer Research 10 2004 718 727
405. R. Zhao Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells Journal of Biological Chemistry 276 2001 1114 1118
406. R. Zhao, and I.D. Goldman Resistance to antifolates Oncogene 22 2003 7431 7457
407. R. Zhao Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway Cancer Research 64 2004 3313 3319
408. R. Zhao, L.H. Matherly, and I.D. Goldman Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues Expert Reviews in Molecular Medicine 11 2009
409. R. Zhao The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption Blood 110 2007 1147 1152
410. R. Zhao A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis Journal of Biological Chemistry 284 2009 4267 4274
411. R. Zhao The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier Molecular Pharmacology 74 2008 854 862
412. R. Zhao Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells Journal of Biological Chemistry 272 1997 21207 21212
413. R. Zhao, I.G. Sharina, and I.D. Goldman Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis Molecular Pharmacology 56 1999 68 76
414. R. Zhao Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase, Journal of Biological Chemistry 275 2000 26599 26606
415. R. Zhao Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis Clinical Cancer Research 11 2005 1294 1301
416. J.Y. Zhou The association between two polymorphisms in the TS gene and risk of cancer: a systematic review and pooled analysis International Journal of Cancer 2012
417. P.A. Zucali Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin Clinical Cancer Research 17 2011 2581 2590